Skip to main navigation Skip to search Skip to main content

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

  • GATHER2 trial investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1449-1458
Number of pages10
JournalThe Lancet
Volume402
Issue number10411
DOIs
StatePublished - Oct 21 2023

ASJC Scopus Subject Areas

  • General Medicine

Cite this